Gartner, Inc. ( MYGN)

FQ1 2012 Earnings Call

November 1, 2011 04:30 pm ET

Executives

Pete Meldrum – President and CEO

Mark Capone – President, Myriad Genetic Laboratories

Jim Evans – Chief Financial Officer

Rebecca Chambers – Director of Investor Relations

Analysts

Scott Gleason – Stephens, Inc.

Jon Wood – Jefferies & Company

Amanda Murphy – William Blair & Company

Tycho Peterson – JP Morgan

Michael Yee – RBC Capital Markets

Isaac Ro – Goldman Sachs

Dave [Kler] – Piper Jaffray

Ashim Anand – Natixis Bleichroeder

Peter Larson – Mizuho Securities

Laura McGuigan – B. Riley

Presentation

Operator

Welcome to Myriad Genetics’ FQ1 Earnings Call. (Operator instructions.) As a reminder, this conference is being recorded Tuesday, November 1, 2011. I would now like to turn the conference over to Rebecca Chambers, Director of Investor Relations. Please go ahead, ma’am.

Rebecca Chambers

Thank you, Lindsey. Good afternoon, everyone, and welcome to the Myriad Genetics’ FQ1 2012 Earnings Call. During the call we will review the financial results we released today and the progress we have made on our strategic directives, after which we will host a question-and-answer session. If you have not had a chance to review the earnings release it can be found in the Investor Relations section of our website at www.myriad.com.

Presenting today will be Pete Meldrum, President and Chief Executive Officer; Mark Capone, President, Myriad Genetic Laboratories; and Jim Evans, our Chief Financial Officer. This call can be heard live via webcast along with the slide presentation at www.myriad.com. The call is being recorded and will be archived in the Investor section of our website.

Please note that some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company’s annual report on Form 10(k), its quarterly reports on Form 10(q), and its current reports on Form 8(k). These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments